Skip to main content
MDGL
NASDAQ Life Sciences

Baker Bros. Buys $35M of Madrigal Stock Days After First Profitable Quarter

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$399.93
Mkt Cap
$9.283B
52W Low
$353.54
52W High
$615
52W Position info
13% above low
Off High info
35% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

MDGL is trading near its 52-week low of $353.54 (13% above the low) on elevated volume (3.1× avg).

Summary

Baker Bros. affiliates bought 91,806 Madrigal shares for $35.0M at $366.99-$396.61, lifting holdings to 2.04M shares — an open-market purchase days after the company's first profitable quarter.


Key Events · Ownership and Investor Activity · MDGL

  • Baker Bros. Buys 91,806 Shares

    Baker Bros. Advisors LP and affiliated reporting persons acquired 91,806 shares for $35,023,032.10 in five open-market transactions on 2026-11-04 and 2026-11-06.

  • Purchase Prices $366.99-$396.61

    Weighted-average fills ranged from $366.99 to $396.61 per share, with the largest single tranche 60,400 shares at $383.015.

  • Holdings Rise to 2.04M Shares

    Post-transaction indirect holdings total 2,040,682 shares, held via 667, L.P. and Baker Brothers Life Sciences LP structures.

  • Follows First Profitable Quarter

    The buying came days after the 2026-11-03 8-K/10-Q reporting $55.4M net income on $431.3M of Rezdiffra sales and $961.8M of cash.


Analysis · MDGL · Life Sciences

Why it matters: Baker Bros. Advisors and its affiliated funds, whose principals hold Madrigal board seats, bought 91,806 shares for $35.0M in the open market on November 4 and 6 — real cash, not option exercises. The timing is notable, coming days after Madrigal reported its first profitable quarter ($55.4M net income on $431.3M of Rezdiffra sales) and one-year data showing up to 93% of patients with improved or stabilized liver stiffness. A specialist biotech investor with board visibility adding at $367-$397 is a meaningful vote of confidence, though at roughly 0.4% of market cap it is a conviction signal rather than a thesis-changing event.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MDGL was trading at $399.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $353.54 to $615.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MDGL - Latest Insights

MDGL
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $408.99
Real-time Price: $379.10 info
Change: -$29.89 (-7%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 9:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $428.01
Real-time Price: $379.10 info
Change: -$48.91 (-11%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $477.00
Real-time Price: $379.10 info
Change: -$97.90 (-21%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $431.16
Real-time Price: $379.10 info
Change: -$52.05 (-12%) info
Market Cap: $8.806B info
MDGL
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $475.00
Real-time Price: $379.10 info
Change: -$95.90 (-20%) info
Market Cap: $8.806B info